Addex Therapeutics (NASDAQ:ADXN) Trading Down 5.9% – Time to Sell?
by Kim Johansen · The Markets DailyAddex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report)’s stock price traded down 5.9% during trading on Thursday . The stock traded as low as $5.72 and last traded at $5.91. 8,666 shares changed hands during trading, an increase of 166% from the average session volume of 3,263 shares. The stock had previously closed at $6.28.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Research Report on ADXN
Addex Therapeutics Stock Performance
The firm has a market cap of $7.27 million, a price-to-earnings ratio of -1.03 and a beta of 1.48. The business’s 50 day moving average price is $7.05 and its 200 day moving average price is $8.04.
About Addex Therapeutics
Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.
The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.